| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA916: Bimekizumab for treating active psoriatic arthritis |
|
Medicine details |
|
| Medicine name | bimekizumab (Bimzelx®) |
| Formulation | 160 mg solution for injection |
| Reference number | 4313 |
| Indication | Treatment of psoriatic arthritis |
| Company | UCB Pharma Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/03/2023 |
| NICE guidance | |